U. Riedel

Learn More
Rituximab (IDEC-C2B8) is a chimeric antibody that binds to the B-cell surface antigen CD20. Rituximab has significant activity in follicular non-Hodgkin lymphomas. Much less is known about the effects in chronic lymphocytic leukemia (CLL). We have initiated a phase II trial to evaluate the efficacy and safety of rituximab in patients with CD20+ pretreated(More)
Our study focuses on the automated generation of detailed gas phase reaction mechanisms for the partial oxidation of iso-octane. The automatically generated mechanism is firstly coupled with a manually written C1-C4 mechanism and validated with respect to ignition delay times from shock tube experiments at different conditions. Besides, coupling of the(More)
The demand of compact and energy saving procedures for the synthesis of H2, synthesis gas and olefins from hydrocarbon fuel is expanding very rapidly as these are essentially needed in fuel cells, additive for fuel and for the cleaning and purification of flue gas. The concern is in particular to more efficient and environmentally more compatible concepts(More)
  • 1